Clinical Trials · NCT01866748
Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 170
- Start date
- May 2013
- Locations
- 1 site, Germany
- Primary endpoint
- Part A: Number of treatment emergent adverse events (TEAEs)